Andi Sukthi
Overview
Explore the profile of Andi Sukthi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parente P, Carbonelli C, Biancofiore G, Sukthi A, Di Micco C, Vairo M, et al.
Thorac Cancer
. 2022 Jul;
13(17):2480-2488.
PMID: 35868633
Background: Lung cancer is the main cause of cancer-related death worldwide, and 85% of all lung tumors are non-small cell lung cancers (NSCLC). More than 60% of all lung tumors...
2.
Vianello A, Arcaro G, Guarnieri G, Sukthi A, Molena B, Turato C, et al.
Arch Bronconeumol
. 2022 Jun;
57(10):666-668.
PMID: 35699054
No abstract available.
3.
Senter R, Capone F, Pasqualin S, Cerruti L, Molinari L, Fonte Basso E, et al.
J Clin Med
. 2021 Apr;
10(6).
PMID: 33804762
Background And Aim: Lung ultrasound (LUS) is a convenient imaging modality in the setting of coronavirus disease-19 (COVID-19) because it is easily available, can be performed bedside and repeated over...
4.
Vianello A, Arcaro G, Guarnieri G, Sukthi A, Molena B, Turato C, et al.
Arch Bronconeumol (Engl Ed)
. 2021 Mar;
PMID: 33676781
No abstract available.
5.
Vianello A, Arcaro G, Molena B, Turato C, Sukthi A, Guarnieri G, et al.
Thorax
. 2020 Jul;
75(11):998-1000.
PMID: 32703883
This observational study aims to assess the outcome and safety of O-therapy by high-flow nasal cannula (HFNC) in 28 consecutive patients with severe hypoxemic acute respiratory failure (hARF) consequent to...
6.
Vianello A, Salton F, Molena B, Turato C, Graziani M, Braccioni F, et al.
J Clin Med
. 2020 Feb;
9(2).
PMID: 32033147
Background: The efficacy and effectiveness of nintedanib as a first-line therapy in idiopathic pulmonary fibrosis (IPF) patients have been demonstrated by clinical trials and real-life studies. Our aim was to...